Douglas E. Coltharp, who serves as Executive Vice President and Chief Financial Officer (CFO) of Encompass Health Corp (EHC), executed a sale of company common stock totaling approximately $2,958,550 on May 15, 2026. The transaction involved the disposition of 27,694 shares of EHC common stock.
The selling price for these shares ranged between $106.28 and $107.28 per share. This range was noted to be in close proximity to the company's prevailing stock price, which stood at $106.88.
Contextual Valuation and Financial Health
The reported insider activity is contextualized by several valuation metrics for Encompass Health. Currently, the stock trades at a Price-to-Earnings (P/E) ratio of 18.34 and a Price/Earnings to Growth (PEG) ratio of 0.75. These ratios suggest that the company may present an attractive valuation relative to its projected growth.
Analysis provided by InvestingPro, which offers comprehensive insights across more than 1,400 US stocks, indicates several aspects of EHC's financial stability. Specifically, the company has maintained continuous dividend payments for a period spanning 14 consecutive years and has reported profitability over the trailing twelve-month period.
Prior Acquisition Activity
It is important to note that prior to this recent sale, Mr. Coltharp had acquired an identical quantity of shares. He obtained 27,694 shares of Encompass Health Common Stock through the exercise of non-qualified stock options. These shares were initially purchased at a price of $32.94 per share, amounting to a total cost of $912,240.
The acquisition details relate to an adjustment in both the number of options and the exercise price, which was pursuant to the 2016 Omnibus Performance Incentive Plan. This plan specifically addressed the spin-off distribution of the common stock belonging to Enhabit, Inc.
Current Holdings and Market Exposure
Following the May 15th transactions, Mr. Coltharp's direct personal holdings in Encompass Health Common Stock total 69,377 shares. His exposure to the company extends further through indirect holdings, which include:
- 27,480 shares held by an irrevocable trust.
- 125,631 shares managed by an irrevocable trust intended for the benefit of children.
- 37,749 shares owned by his spouse.
Collectively, these holdings maintain a significant financial exposure to Encompass Health's market capitalization, which is valued at $10.61 billion.
Broader Corporate Developments
In other recent announcements, Encompass Health Corp has detailed several strategic financial and operational initiatives. The company announced the pricing for a private offering of $500 million in senior notes, which are due in 2034 and carry an interest rate of 5.875%. These notes will be secured by both the corporation's current and future subsidiaries.
Operationally, Encompass Health revealed plans to construct a new 50-bed inpatient rehabilitation hospital located in Post Falls, Idaho. This facility is designated to provide specialized care for patients presenting with a variety of medical conditions.
Furthermore, the company declared a quarterly cash dividend of $0.19 per share, scheduled to be payable in July 2026.
From an investment perspective, Truist Securities reiterated its Buy rating on Encompass Health. The firm supported this rating by referencing strong first-quarter results, noting that the adjusted EBITDA had exceeded expectations. Despite a minor dip in trading volumes, Truist highlighted the continued robust cash flow generation and an upward revision in the company's guidance.
These cumulative developments underscore Encompass Health’s ongoing strategic efforts across its financial structure and operational footprint.